查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1673817

製药和生物技术临床阶段合作条款和协议（2020-2025年）

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025
出版日期: | 出版商: Current Partnering | 英文 1500+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告研究了製药和生物技术行业的临床阶段合作条款和协议，并提供了全面的资料驱动分析，说明公司如何以及为何签订临床阶段合作协议，以及这些协议所依据的财务和战略条款。本报告还提供了有关製药和生物技术行业临床阶段药物开发合作的交易结构、谈判动态和财务考虑的无与伦比的见解。

在临床阶段，授权协议通常授予被授权人开发授权人产品或技术的独家权利或选择权，通常涵盖第一阶段、第二阶段和第三阶段试验。此类协议通常包含多项内容，包括共同研发、共同开发和商业化策略。

本报告提供了医疗保健领域当前临床阶段交易的详细资讯，可以帮助公司评估市场趋势，最佳化谈判策略和基准交易结构。

本报告提供：

  • 2020年及以后生物製药产业临床阶段交易趋势分析
  • 详细的合约结构，包括总金额、里程碑、特许权使用费等。
  • 实际临床阶段合约案例研究
  • 可查阅超过 1,670 例临床阶段病例（如有合约记录，另行提供）
  • 2020年及以后最活跃的临床阶段交易者的合作伙伴简介
  • 对最高价值临床阶段交易进行详细分析

目录

执行摘要

第1章 简介

第2章 为什么各公司要在临床阶段化合物上合作？

  • 临床阶段联盟的作用
    • 临床阶段的许可
    • 临床阶段许可
  • 第一阶段、第二阶段与第三阶段交易的差异
  • 为什么要签订临床阶段合作协议？
    • 授权方为何参与临床阶段交易
    • 为什么被授权者要达成临床阶段交易
  • 临床阶段合作协议的未来

第3章 临床阶段交易策略与结构

  • 公司在什么阶段进行合作？
    • 製药/生技领域的早期合作
    • 製药/生技联盟
  • 早期与晚期伙伴关係：风险与成本
  • 各公司在临床阶段合作上花了多少钱？
  • 纯合作协议与多部分合作协议
  • 纯许可协议的结构
    • 纯许可协议范例
    • 个案研究
  • 多部分临床阶段合作协议
    • 多部分临床阶段条款范例
    • 个案研究

第4章 临床阶段合作伙伴付款策略

  • 临床阶段付款策略
  • 付款方式
    • 标题
    • 预付
    • 贷款
    • 可转换贷款
    • 公平
    • 研发资金
    • 许可证费用
    • 里程碑
    • 版税
    • 现金
    • 选择

第5章 临床阶段交易趋势

  • 长期临床阶段合作
    • 2020年及以后第一阶段的交易趋势
    • 2020年以后的第二阶段交易趋势
    • 2020年以后的第三阶段交易趋势
  • 依交易类型划分的临床阶段伙伴关係
  • 依疾病类型划分的临床阶段合作
  • 依技术类型划分的临床阶段合作伙伴关係
  • 2020年以来最活跃的企业临床阶段合作伙伴关係

第6章 临床阶段合作付款条款

  • 临床付款条款指南
    • 预付
    • 里程碑
    • 版税
  • 临床阶段付款条款：交易资料分析
    • 公开资料
    • 调查资料
  • 付款条件分析
    • 临床阶段合作的头条付款
    • 临床阶段交易的预付款
    • 临床阶段交易的里程碑付款
    • 临床阶段专利使用费率
  • 临床阶段财务中位数
    • 临床阶段主要资料
    • 临床阶段预付款金额
    • 临床里程碑金额
    • 临床阶段特许权使用费金额

第7章 关键临床阶段交易

  • 依价值排名的顶级临床阶段交易

第8章 25 大临床阶段交易者

  • 25 大最活跃的临床阶段交易者

第9章 临床阶段合作协议目录

  • 自2020年起的临床阶段商业协议

第10章 临床阶段交易（依开发阶段划分）

  • 依临床阶段划分的交易
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 申请阶段

附录

关于 Wildwood Ventures

简介目录
Product Code: CP2058

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies engage in clinical-stage partnering agreements, as well as the financial and strategic terms shaping these collaborations. This essential industry resource delivers unparalleled insights into deal structures, negotiation dynamics, and financial considerations for clinical-stage drug development partnerships.

At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies.

This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

  • Benchmarking deal structures and financial terms
  • Optimizing negotiation strategies
  • Assessing potential partners' flexibility
  • Identifying trends in clinical-stage partnerships
  • Why This Report is Essential for Dealmakers
  • Understanding the flexibility and negotiation strategies of potential partners is critical when structuring clinical-stage partnerships. While headline financial terms (e.g., upfront payments, milestones, royalties) provide a broad overview, contract documents reveal the actual triggers and conditions for these payments-details often missing from press releases and traditional deal databases.
  • This report provides a comprehensive listing of over 1,670 clinical-stage deals announced since 2020, including financial terms where available. Additionally, it features direct links to online deal records, along with publicly available contract documents submitted to the SEC.
  • By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
  • Comprehensive Analysis of Clinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to clinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in clinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of clinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates for Phase I, Phase II, and Phase III deals

Chapter 7 - A review of the leading clinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active clinical-stage dealmakers

Chapter 9 - A database of clinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all clinical-stage deals announced since 2020, categorized by Phase I, Phase II, and Phase III

  • Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own clinical-stage partnerships. Key benefits include:

  • Unparalleled Market Insights - Gain a deep understanding of clinical-stage deal trends shaping the pharma and biotech industry since 2020.
  • Exclusive Financial Data Access - Unlock headline values, upfront payments, milestone structures, and royalty terms, giving you a competitive edge in deal negotiations.
  • Comprehensive Deal Database - Access a curated repository of over 1,670 clinical-stage agreements, including contract documents where available, for unmatched transparency and benchmarking.
  • Deep-Dive into Industry Leaders - Analyze actual clinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging biopharma players.
  • Proven Case Studies & Structural Analysis - Examine real-world deal structures and case studies to refine your own partnering and negotiation strategies.
  • High-Value Deal Identification - Pinpoint the most lucrative clinical-stage deals signed since 2020, gaining insight into premium industry transactions.
  • Profile the Most Active Dealmakers - Identify the key players driving clinical-stage collaborations, ensuring you target the right partners.
  • Strategic Deal Mapping - Navigate a full A-Z listing of clinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
  • Negotiate with Confidence - Understand the key terms and conditions top-tier companies have agreed to in previous deals, helping you structure optimal agreements.
  • Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms with potential partners.
  • Report Scope

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

  • Trends in clinical-stage dealmaking in the biopharma industry since 2020
  • Detailed deal structures, including upfront, milestone, and royalty terms
  • Case studies of real-life clinical-stage agreements
  • Access to over 1,670 clinical-stage deals, with contract records where available
  • Partnering profiles of the most active clinical-stage dealmakers since 2020
  • Analysis of the highest-value clinical-stage deals

Each deal record is indexed by:

  • Company (A-Z)
  • Headline Value
  • Stage of Development at Signing (Phase I, Phase II, Phase III)
  • Deal Type
  • Specific Therapy Focus
  • Critical Questions Answered

By analyzing actual contract agreements, this report provides definitive answers to critical questions such as:

  • What specific rights are granted in each agreement?
  • What exclusivity terms apply?
  • How is the deal structured financially? (Upfronts, milestones, royalties)
  • Who controls development, manufacturing, and commercialization?
  • How are intellectual property rights handled?
  • What are the termination conditions for the agreement?
  • What dispute resolution mechanisms are in place?
  • How are confidentiality and publication rights managed?
  • Gain the competitive edge-explore the report today.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

  • 2.1. Introduction
  • 2.2. The role of clinical stage partnering
    • 2.2.1. In-licensing at clinical stage
    • 2.2.2. Out-licensing at clinical stage
  • 2.3. Difference between phase I, II and III stage deals
  • 2.4. Reasons for entering into clinical stage partnering deals
    • 2.4.1. Licensors reasons for entering clinical stage deals
    • 2.4.2. Licensees reasons for entering clinical stage deals
  • 2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent clinical stage partnering agreements
    • 3.7.1. Example multicomponent clinical stage clauses
    • 3.7.1.a. Case study 11

Chapter 4 - Clinical stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Clinical stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 12
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

  • 5.1. Introduction
  • 5.2. Clinical stage partnering over the years
    • 5.2.1. Trends in phase I deals since 2020
    • 5.2.1.1. Attributes of phase I deals
    • 5.2.2. Trends in phase II deals since 2020
    • 5.2.2.2. Attributes of phase II deals
    • 5.2.3. Trends in phase III deals since 2020
    • 5.2.3.1. Attributes of phase III deals
  • 5.3. Clinical stage partnering by deal type
  • 5.4. Clinical stage partnering by disease type
  • 5.5. Partnering by clinical stage technology type
  • 5.6. Clinical stage partnering by most active company since 2020

Chapter 6 - Payment terms for clinical stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for clinical stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Clinical stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Clinical stage partnering headline values
    • 6.4.2. Clinical stage deal upfront payments
    • 6.4.3. Clinical stage deal milestone payments
    • 6.4.4. Clinical stage royalty rates
  • 6.5 Clinical stage median financials
    • 6.5.1. Clinical stage headline value
    • 6.5.2. Clinical stage upfront value
    • 6.5.3. Clinical stage milestone value
    • 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

  • 7.1. Introduction
  • 7.2. Top clinical stage deals by value

Chapter 8 - Top 25 most active clinical stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Clinical stage deals with contracts since 2020

Chapter 10 - Clinical stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by clinical stage
  • Phase I
  • Phase II
  • Phase III
  • Regulatory

Appendices

  • Appendix 1 - Clinical stage dealmaking by companies A-Z
  • Appendix 2 - Clinical stage dealmaking by industry sector
  • Appendix 3 - Clinical stage dealmaking by stage of development
  • Appendix 4 - Clinical stage dealmaking by therapy area
  • Appendix 5 - Clinical stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of clinical phases in dealmaking
  • Figure 2: Components of the pure licensing deal structure
  • Figure 3: Payment options for clinical stage partnering deals
  • Figure 4: Issues affecting royalty rates
  • Figure 5: Clinical stage partnering by deal type since 2020
  • Figure 6: Clinical stage partnering by disease type since 2020
  • Figure 7: Clinical stage partnering by technology type since 2020
  • Figure 8: Top 25 most active clinical stage dealmakers, 2020 - 2025
  • Figure 9: Review of upfront payments for clinical stage deals
  • Figure 10: Review of milestone payments for clinical stage deals
  • Figure 11: Review of royalty payments for clinical stage deals
  • Figure 12: Clinical stage deals with a headline value
  • Figure 13: Clinical stage deals with an upfront value
  • Figure 14: Clinical stage deals with a milestone value
  • Figure 15: Clinical stage deals with a royalty rate value
  • Figure 16: Top clinical stage deals by value since 2020
  • Figure 17: Most active clinical stage dealmakers 2020 - 2025